Advertisement

Antineoplastic Agents

  • P. N. Patsalos
Chapter

Abstract

Carbamazepine Carbamazepine enhances the mean plasma clearance of 9-aminocamptothecin by 68 % and can decrease median plasma 9-aminocamptothecin levels by 67 % 1.

Keywords

Valproic Acid Active Metabolite Plasma Clearance Intermediate Metabolite Protein Binding Displacement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S. Increased 9-aminocamptothecin dose requirements in patients with anticonvulsants. Cancer Chemother Pharmacol. 1998;42:118–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33:181–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 Enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008;10:190–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatine-based chemotherapy associated with valproate: increase of haematologic activity. Ann Oncol. 2001;12:217–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR. Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. Cancer Chemother Pharmacol. 2009;63:543–7.PubMedCrossRefGoogle Scholar
  7. 7.
    de Jong ME, Huitema ADR, van Dam AM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol. 2005;55:507–10.CrossRefGoogle Scholar
  8. 8.
    Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukemia. Lancet. 2000;356:285–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol. 1994;12:2390–7.PubMedGoogle Scholar
  10. 10.
    Chhun S, Verstuyft C, Rizzo-Padoin N, Simoneau G, Becquemont L, Peretti I, Swaisland A, Wortelboer R, Bergmann JF, Mouly S. Gefitinib-phenytoin interaction is not correlated with the 14C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009;68:226–37.PubMedCrossRefGoogle Scholar
  11. 11.
    van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich CV, de Jong MJA, Brandes A, Frenay M, Carpentier AF, Cholllet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P. European Organisation for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol.2003;14(12):1732–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Lokiec F, Santoni J, Weill S, Tubiana-Hulin M. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs. 1996;7:893–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Ghosn M, Carde P, Leclerq B, Flamant F, Friedman S, Droz JP, Hayat M. Ifosfamide/mesa related encephalopathy: a case report with possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer. 1988;74:391–2.Google Scholar
  14. 14.
    Ducharme MP, Bernstein ML, Granvil CP, Gehrcke B, Wainer IW. Phenytoin-induced alteration in the N-dechloroethylation of ­ifosfamide stereoisomers. Cancer Chemother Pharmacol. 1997;40:531–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Pursche S, Schleyer E, von Bonin M, Ehningger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhauser M, Dresemann G. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol. 2008;3:198–203.PubMedCrossRefGoogle Scholar
  16. 16.
    Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359–68.PubMedCrossRefGoogle Scholar
  17. 17.
    Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CF, Crews KR. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in patients who have high-grade gliomas receiving enzyme-inducing anticonvulsant therapy. Cancer. 2003;95 (Suppl):2374–80.CrossRefGoogle Scholar
  18. 18.
    Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacological modulation or irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004;76:490–502.PubMedCrossRefGoogle Scholar
  19. 19.
    Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940–9.PubMedGoogle Scholar
  20. 20.
    de Jong FA, van der Bol JM, Mathijssen RHJ, Loos WJ, Mathot RAA, Kitzen JJEM, van den Bent MJ, Verweij J. Irinotecan chemotherapy during valproic acid treatment. Pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther. 2007;6:1368–74.PubMedGoogle Scholar
  21. 21.
    Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2009;67:421–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J Neurooncol. 2000;48:249–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Chang SM, Kuhn JG, Rizzo J, Robins HA, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol. 1998;16:2188–94.PubMedGoogle Scholar
  24. 24.
    Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther. 1997;62:225–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Grossman SA, Carson KA, Batchelo TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006;12:5174–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medication. J Clin Pharmacol. 2007;47:1430–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol. 1992;10:311–5.PubMedGoogle Scholar
  28. 28.
    de Jong ME, Huitema ADR, van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol. 2005;55:507–10.CrossRefGoogle Scholar
  29. 29.
    Zamboni WC, Gajja AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res. 1998;4:783–9.PubMedGoogle Scholar
  30. 30.
    Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999;66:589–93.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations